like we didn't know that was coming. Shorts can't get enough shares at the levels they want so they let it recover on low volume and short it back down with higher volume. Really kind of simple. Longs may not want to hear this but this stock is NOT ready to run anytime soon.
and here's why. The overall market is getting heavy again flirting with 18,000. Typically this has not held and the market will correct about 5% over several weeks to low 17,000s. Look for a retreat to mid $4s again.
Look for a 40% reversal by md next week. They will let it play out this week and slam it hard next week and everyone will die to get back out. In the long run, this was a short squeeze on high volume but it will regulate itself in a matter of days. Count on it! No position, just lots of experience with these knee jerk responses to sallow news events.
It was used an excuse so they didn't have to market it. They will sell the drug and not market it. If they were, we would have heard about marketing materials being printed, sales people being interviewed (hired) while they waited. This is a smoke screen to sit back and do nothing, conserve cash and make themselves look as attractive as possible to a possible suitor. That's my take.
Shorts are protecting it with a vengeance. Very few hits at that level. As soon as it drops, the covering begins again and when at $1.30, the action dries up.
Everything is in line but we need doctor's to change to urine based testing or we just become another good idea that never was! Revenue is what it's all about, period. Speculation means nothing anymore. People pay for results!
11:01 am TrovaGene presents clinical results demonstrating highly sensitive detection of EGFR T790M mutations in the urine of patients with non-small cell lung cancer at 2016 ASCO (TROV) :
You are a freakin dreamer. Lets buy a company for $35 a share when we could have bought hand over fist at $5. Yeah those companies last long.
Drop it low, run it high, flat line to the close. So boring. This stock needs a major kick in the #$%$! Glad to see the ASCO presentation vaulted us up 20% with a BO. Yeah right!
That's all I heard about the last few weeks, now that its 24 hours away, where are all the chest pumpers? They all but broadcasted a 10-20% gain since it's such big deal for TROV. Well, there is no talk about it which means the MM saw the briefing and they have nothing to worry about as usual. Just another date on the calendar I suppose.
You hit it on the head. The article was about blood biopsy not urine which is why TROV was not mentioned. If truth be told, the blood guys are getting nervous because of this new technology.
But if their negative hype works and causes the price to drop, be assured they will be there buying hand over fist, like most low life #$%$ analysts.